Cartesian Therapeutics Inc. (RNAC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $193.69M
Last updated: Nov 17, 2026 at 11:05 AM ET
Performance (10Y)
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 14.1% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 38.6, in the neutral range between 30 and 70.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about RNAC
News
RNAC Valuation
Cartesian Therapeutics (RNAC) trades at 25.1x forward earnings.
- Forward P/E
- 25.1x
- P/FCF
- -2.0x
- P/B
- -1.4x
RNAC Profitability: Margins, ROIC and FCF
Cartesian Therapeutics (RNAC) has an operating margin of -10009.0% and a net margin of 0.0%. It posts 147.2% ROIC and a -8770.0% FCF margin.
- Operating margin
- -10009.0%
- Net margin
- 0.0%
- ROIC
- 147.2%
- ROE
- -7029.0%
- FCF margin
- -8770.0%
- FCF yield
- -48.8%
Cartesian Therapeutics Competitors
The companies most similar to Cartesian Therapeutics (RNAC) include SAB Biotherapeutics, Cellectis SA and Sutro Biopharma.
Sector: Healthcare
Companies most similar to Cartesian TherapeuticsRNAC Analyst Ratings
Cartesian Therapeutics (RNAC) has a Buy consensus from 7 analysts: 7 Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell.
- Consensus
- Buy
- Analysts
- 7
- Strong Buy
- 1
- Buy
- 6
- Hold
- 0
- Sell
- 0
- Strong Sell
- 0
RNAC Bull Case vs Bear Case
Bull case
- RNAC earns a 147.2% return on invested capital.
- 100.0% of RNAC's analyst ratings are Buy or Strong Buy.
Bear case
- RNAC's quarterly revenue changed -92.9% year over year.
RNAC Earnings: Beat Rate and Next Report
Cartesian Therapeutics (RNAC) beat the EPS estimate in 5 of the last 8 quarters (62.5%). Its next report is expected on Mar 8, 2027.
- Beat rate
- 5 of 8 quarters (62.5%)
- Average surprise
- 15.8%
- EPS estimate (fiscal period ending Dec 31, 2026)
- -$0.95
RNAC Earnings Date
RNAC reports Mar 8, 2027. The date is estimated.
RNAC ETF Holders
GNG tracks 7 ETFs that hold RNAC. The largest weights:
- Fidelity Growth Company K6 Fund (FGKFX), <0.01% of the fund
- Fidelity Growth Company Fund (FDGRX), <0.01% of the fund
- Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
- iShares Russell 2000 ETF (IWM), <0.01% of the fund
- Vanguard Morningstar Total Stock Market ETF (VTI), <0.01% of the fund
Updated Nov 5, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About RNAC
When does RNAC report earnings?
Cartesian Therapeutics Inc. (RNAC) is expected to report earnings on Mar 8, 2027.
Does RNAC pay dividends?
Cartesian Therapeutics Inc. (RNAC) does not currently pay a regular dividend.
What is RNAC's market cap?
Cartesian Therapeutics Inc. (RNAC) has a market capitalization of $193.69M with a current stock price of $6.08.
RNAC pages: Overview, Earnings, Forecast, Financials, Competitors
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.